Michele Imparato
Overview
Explore the profile of Michele Imparato including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rinaldi L, Messina V, Di Marco V, Iovinella V, Claar E, Cariti G, et al.
Am J Gastroenterol
. 2021 Jun;
116(6):1248-1255.
PMID: 34074828
Introduction: We assessed the performance of direct-acting antivirals (DAAs) in hepatitis C virus (HCV)-infected people who use drugs (PWUDs) in terms of sustained virological response (SVR) and adherence rates in...
2.
De Luca M, Addario L, Lombardi A, Imparato M, Fontanella L, Addario M, et al.
J Gastrointestin Liver Dis
. 2021 Feb;
30(1):94-102.
PMID: 33548124
Background And Aims: Patients with liver cirrhosis (LC) often have malnutrition (MN), which can be associated with decompensation, infection, and death. The aims were to determine: the prevalence of MN...
3.
Di Micco P, Imparato M, Lubrano G, Iannuzzo D, Fontanella L, Improta L, et al.
Medicina (Kaunas)
. 2021 Jan;
57(2).
PMID: 33498929
COVID-19 has been associated with a hypercoagulable state and thrombotic events. Venous thromboembolism has been the most commonly reported type of thrombosis but also arterial thrombosis and disseminated intravascular coagulation...
4.
Di Micco P, Russo V, Carannante N, Imparato M, Cardillo G, Lodigiani C
J Clin Med
. 2020 Dec;
9(12).
PMID: 33371524
Introduction: A highly pathogenic human coronavirus able to induce severe acute respiratory syndrome (SARS) has been recently recognized as the cause of the coronavirus disease 2019 (COVID-19); the disease became...
5.
Di Micco P, Di Micco G, Russo V, Poggiano M, Salzano C, Bosevski M, et al.
J Blood Med
. 2020 Jul;
11:237-241.
PMID: 32694923
While waiting for the vaccine and/or the best treatment for COVID19, several drugs have been identified as potential adjuvant drugs to counteract the viral action. Several drugs, in fact, have...
6.
Di Micco P, Russo V, Carannante N, Imparato M, Rodolfi S, Cardillo G, et al.
J Clin Med
. 2020 May;
9(5).
PMID: 32392741
Introduction: A novel highly pathogenic human coronavirus able to induce severe acute respiratory syndrome (SARS) has been recently recognized as the cause of the coronavirus disease 2019 (COVID-19) outbreak, which...
7.
Rinaldi L, Guarino M, Perrella A, Pafundi P, Valente G, Fontanella L, et al.
Dig Dis Sci
. 2019 Apr;
64(10):3013-3019.
PMID: 30937719
Purpose: The aim of this study was to evaluate the relationship between the liver stiffness measurement and the risk of developing hepatocellular carcinoma (HCC) in HCV cirrhotic patients undergoing new...
8.
Ascione A, Fontanella L, Imparato M, Rinaldi L, De Luca M
Liver Int
. 2017 Jan;
37(8):1193-1201.
PMID: 28111883
Background & Aims: Cirrhosis (LC) and hepatocellular carcinoma (HCC) are highly prevalent in Europe, with accompanying high mortality rates and social costs. As epidemiological data on these diseases are scarce,...
9.
Cleo Study Group , Ascione A, Adinolfi L, Amoroso P, Andriulli A, Armignacco O, et al.
World J Hepatol
. 2016 Aug;
8(22):949-56.
PMID: 27574549
Aim: To check the safety and efficacy of boceprevir/telaprevir with peginterferon/ribavirin for hepatitis C virus (HCV) genotype 1 in the real-world settings. Methods: This study was a non-randomized, observational, prospective,...
10.
Di Costanzo G, de Stefano G, Tortora R, Farella N, Addario L, Lampasi F, et al.
Future Oncol
. 2015 Mar;
11(6):943-51.
PMID: 25760975
Aim: Sorafenib is the standard of care in advanced hepatocellular carcinoma. This study was aimed to identify clinical parameters that may predict survival in these patients. Materials & Methods: In...